November 17, 2011
Hillary A. Prescott, PharmD, BCOP
Clinical Pharmacy Specialist, Leukemia
Division of Pharmacy, University of Texas M.D. Anderson Cancer Center
Houston, Texas
Jeffrey C. Bryan,...
January 22, 2010 Abstract
The adequacy of labeling for instructions, cautions, and contraindications becomes pivotal in the benefit/risk assessment of medical products. Our...
January 6, 2010 Coordinating REMS activities between the various functional groups within a pharmaceutical company that are involved in, or are affected by...
January 5, 2010 The objective of these periodic REMS knowledge and understanding assessments is to track stakeholder recognition and comprehension of the product...
January 1, 2010 A Dear Healthcare Professional (HCP) Letter is a risk communication tool that is often included as an element of a...
